| Objective:The clinical manifestation of coronary heart disease is determined by the ingredients of the coronary atherosclerotic plaque . If not accompanied by formation of thrombus,the course of simple stenosis of coronary artery is benign which shows no symptoms or stable angina pectoris.But as the plaque rupture was appeared, thrombus was formed subsequently, then the course will be deteriorated, and become an acute coronary syndromes(ACS).ACS includes unstable angina pectoris, acute myocardial infarction and sudden death. Transformating stable plaque to unstable plaque is due to many factors ,in which the mainfactors are change of plaque structure and inflammation . More and more evidences suggest that the plaque rupture induced by local inflammatory cells is a important mechanism for the onset of ACS . A variety of major long-term clinical trials of lowering lipid have raised our knowledge of the pathophysiology of coronary atherosclerosis and ischemia. It is evidenced that except the effect of lipid lowering, statins also can modify endothelial dysfunction, stabilize plaque, block inflammation and reducecoronary events. Therefore, it is beneficial to apply statins in the early stage of ACS. Additional studies are needed to confirm the benefit of early statin treatment in patients with ACS and to elucidate the mechanism of statins acting on ACS. The patients with ACS used Atovastatin early were observed the variations of interleukin-6(IL-6) and C-reactive protein (CRP) levels and evaluated its effect of anti-inflammtion and benefits to ACP prognosis. Methods: 56 patients with ACS were enrolled (35 men ,21 women;age 43-79, average 61.3±8.43 years). The patients all correspond to the diagnosis criteria of AMI and UAP in WHO. The following disease were excluded :such as infectious disease,tumor,selfimmunized disease,heart failure,diabetes,the patient took lipid lowering agents the last 2 weeks,the patient with hepatic or renal impairment. Subjects were randomized to atovastatin (28cases) or routine therapy(28cases)groups. Atovastatin group (17 men, 11 women; age 43~79, average 61±8 years; 18 UAP, 10AMI), routine group(18 men,10 women; age 44~78, average 60.92±8.38 years;19 UAP or 9 AMI). An age, sex , hypertension, heart rate, blood pressure, serum lipid, CK peak value and drug uses between atovastatin and routine group were not significant differences. In addition, 28 stable angina pectoris (SAP)patients were selected as a control group(19men,9women; age 43~77 average 61.12±8.27). The patients all correspond to the diagnosis criteria of SAP inWHO. All patients excludes infectious disease,tumor,selfimmunized disease .Both groups were all treated by routine therapy, on this basis,20 mg atovastatin were given once a day before sleep in atovastatin group,all patients in the two groups were not given anti-inflammatory drugs, then IL-6,CRP and blood lipid were measured before treatment and after 3 weeks respectively.The levels of IL-6 was measured by radioimmunoassay,and the level of CRP were measured by ELISA. The occurrence of UAP, AMI and death are all observed in 3 months during the period inside and outside of the hospital. Statistics work was done with SPSS.10.0 statistical software.Results: The levels of IL-6 and CRP in all of the patients were higher than those in control group. In atovastatin group, the levels of IL-6 and CRPafter therapy were decreased significantly than those before therapy(P<0.05). There were significant differences in the levels of the two parameters between atovastatin and routine group(P<0.05). The values of IL-6 and CRP were improved slightly in routine group than those before therapy, but it is not significant difference(P>0.05). There were a positive correlative between IL-6 and CRP values. The changes of blood lipid in both groups: After therapy, blood lipid values were decreased in taking atovastatin group, but only TC and LDL cholesterol were decreased significantly. Follow up<...
|
PDF Full Text Request